GlassScriptPhysician profile
Tracy A Starnes
NPI 1649413261
$7,752.37
in general payments reported to CMS, 2019-2025
48 companies · $829 in 2025
The $829 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,079 · 2022: $1,797 · 2023: $1,636 · 2024: $1,411 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,876.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $858.55 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $806.81 | 2021-2025 | |
| Lilly USA, LLC | $581.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $524.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $487.62 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $458.33 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.01 | 2021-2025 | Jardiance |
| Amgen INC. | $333.71 | 2021-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $326.35 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Phathom Pharmaceuticals, INC. | $203.56 | 2023-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $183.68 | 2021 | |
| Abbott Laboratories | $171.63 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2, Jot Dx |
| Idorsia Pharmaceuticals US INC | $164.42 | 2022-2024 | Quviviq |
| Impel Pharmaceuticals INC. | $156.05 | 2022-2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $143.71 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Starnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.